Positive Clinical Data for Pulse Biosciences
Bioelectric medicine company, Pulse Biosciences (Nasdaq: PLSE) has announced positive clinical data from an FDA approved Investigational Device Exempt treat and resect study on the use of its Nano-Pulse Stimulation™ (NPS) technology for low-risk basal cell carcinoma lesions.
The company presented the data at the 2022 American Society for Dermatologic Surgery Annual Meeting this month.
- The study showed complete clearance of basal cell carcinoma lesions using NPS technology;
- NPS is a potential alternative to the current standard of care for these types of lesions;
- Basal cell carcinoma is the most common form of skin cancer, accounting for 67% of all skin cancers and affecting more than 3.6 million patients annually;
- Current standard treatments – excisional and micrograph surgeries – can lead to scarring. NPS technology is non-surgical and has a lower likelihood of scar formation.
Pulse Biosciences’ proprietary NPS technology delivers nano-second pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.